Prostate cancer: the PSA that starts the conversation, the slow form and the fast form, and the choices between watching and treating
Last updated September 3, 2026.
Prostate cancer grows in the gland at the base of a man's bladder, and it is the commonest cancer in men, and the single most important thing to know about it is that it is not one disease but a spectrum: a slow form that many men, especially older men, die with rather than of, and a fast form that needs treatment. The modern pathway is built around telling them apart before treating, because the treatments, surgery and radiotherapy, cure well but carry real costs in continence and sexual function. The conversation usually starts with a PSA blood test, sometimes a digital rectal examination, then an MRI, then a biopsy if the picture warrants it, and the biopsy grades the cancer, which is what sorts the spectrum. Low-risk cancers are increasingly managed with active surveillance, regular PSA tests, examinations, and repeat scans and biopsies, treating only if the cancer shows signs of waking, and the studies show men on surveillance live as long as men treated immediately. Higher-risk cancers get treated with intent to cure: surgery to remove the prostate, radiotherapy often with hormone therapy, and the spread disease is managed with hormone therapy and the newer medicines for years. The worth-knowing parts: urinary symptoms are usually the prostate's benign enlargement, not cancer; Black men and men with a family history carry higher risk and should talk about testing earlier; and the side-effect conversation, continence and erections, deserves as much time as the cure conversation, because both are part of choosing well.
What does it look like?
Early prostate cancer usually looks like nothing: most is found on a PSA test or an examination in a man who feels well. Urinary symptoms, poor flow, frequency, night-time trips, are usually the benign enlargement, not cancer. The spread disease can announce as new persistent bone pain, especially in the back and hips, weight loss, or fatigue, which is why persistent bone pain in an older man earns a PSA test.
Why does it happen?
Prostate cells acquire DNA damage and grow without the controls, driven by age, the biggest factor, by inherited risk, a father or brother with the disease or the breast and ovarian cancer genes in the family, and by ethnicity, with Black men carrying roughly double the risk. It is not caused by cycling, sex, or a vasectomy. Most men over eighty harbor some if looked for, which is the slow form's argument for sorting before treating.
How is it treated?
- Low-risk disease is watched, actively. Active surveillance tracks the PSA, the examination, and repeat scans and biopsies, treating only if the cancer shows signs of waking, and men on surveillance live as long as men treated immediately, avoiding the side effects in the meantime.
- Surgery or radiotherapy cures the contained fast-growing cancer. Removal of the prostate, or radiotherapy often with hormone therapy, are the curative options, and the choice between them is a real conversation about side-effect profiles, not a default.
- Spread disease is managed for years. Hormone therapy and the newer medicines control it, often for a long time, with the bone health and the cardiovascular side of the hormones managed alongside.
- The side effects get treated as seriously as the cancer. Continence rehabilitation, erectile-function support, and the psychological weight all have their own services, and asking for them is standard, not soft.
When does it need prompt advice?
Inability to pass urine is a same-day emergency. New severe back pain with leg weakness or numbness, or loss of bladder or bowel control, in a man with known prostate cancer is an emergency, the spine is being pressed. New persistent bone pain earns a prompt appointment. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
How can I possibly choose to leave cancer inside me?
By knowing which cancer it is, because low-risk prostate cancer is the slow form, the one the studies say most men die with rather than of, and the word cancer is doing work in your head that this particular cancer has not earned. The landmark trial randomized men like you between surgery, radiotherapy, and monitoring, and at fifteen years the survival was the same in all three: the monitoring men were not gambling, they were matching. Active surveillance is also not ignoring it: it is a tight schedule of PSA tests, examinations, scans, and repeat biopsies whose whole job is to catch the cancer if it shows signs of waking, and treatment at that point still cures. About half of men on surveillance never need treatment at all, which means half of the men who chose it avoided the side effects entirely for a cancer that never moved.
If the outcomes are the same, why does anyone have the surgery?
Because the fork is values-shaped, not evidence-shaped, and different men weigh it differently. Some cannot sleep with the cancer in them, and for those men the certainty of removal is worth the side-effect risk, and that is a rational trade, not an irrational one. Some cancers sit at the higher end of low-risk and tip toward treatment on the numbers. And the side-effect profiles differ in timing, which men weigh by their own priorities: surgery's continence and erection costs arrive immediately and often improve; radiotherapy's arrive later and can accumulate. Your brother's advice is one temperament's answer, formed in a decade before the surveillance evidence was this strong. The deciding questions that help: how much will the cancer's presence cost me in sleep, and how much do the side-effect profiles matter to me at my age? Answer those honestly and the choice usually makes itself.
What does active surveillance actually involve, and is it safe?
It is a schedule, not a shrug, and the schedule is the safety. The typical program: PSA blood tests every few months at first, a periodic examination, a repeat MRI at intervals, and a repeat biopsy on a schedule or when the numbers move. The whole apparatus exists to catch change early, and the safety data is the fifteen-year trial showing men watched this way live as long as men treated immediately, with the treated-early men having carried the side effects the whole time. If the cancer shows signs of waking, the recommendation shifts to treatment, and treatment at that point cures at the same rate as treating on day one. The commitment it asks of you is real: the appointments are the treatment, and the man who chooses surveillance and skips the schedule has chosen neither option properly.
What are the real side effects of surgery and radiotherapy?
Both cure well, and both send a bill, and the bills differ in timing. Surgery, removing the prostate: the immediate costs are some months of urinary leakage, improving with pelvic-floor rehabilitation, and erection difficulties that affect most men at first and recover to varying degrees over one to two years, better in younger men with nerve-sparing operations. Radiotherapy: the costs arrive later, gradual erection decline over years, some bowel irritation and urgency, and a small long-term risk of urinary irritation. Both affect fertility and ejaculation permanently. The numbers for your exact situation come from the specialists, and the side-effect conversation deserves as much appointment time as the cure conversation, because at low-risk the choice between the options is mostly a choice between the bills. Asking for the continence and erectile services is standard, not soft.
My brother had his out and says just get it out. How do I weigh his view?
As one man's temperament, formed in a different evidence era, and not as your answer. His advice comes from a real place: his operation worked, he is well, and the decade he was treated in tilted much more strongly toward treating everything, because the surveillance evidence was not yet this strong. But his cancer was his, its grade unknown to you and possibly higher-risk than yours, and his temperament, the cannot-sleep-with-it-in-me kind, is one of the legitimate answers, not the only one. The man who chooses surveillance with the trial data behind him is not being braver or more foolish than your brother; he is answering the same two questions, the sleep cost and the side-effect weight, with different values. Thank your brother for the view, note that his outcome is part of what makes surgery a good option when chosen, and decide as the man with your biopsy, not his.
Should I have any symptoms by now? I feel completely well.
Feeling well is the rule, not the exception, and it is worth knowing why: early prostate cancer almost always causes no symptoms at all, which is precisely why it is found on PSA tests and examinations in men who feel fine, like you. The urinary symptoms men dread, the poor flow, the night-time trips, are usually the prostate's benign enlargement, which nearly every man your age has to some degree, and they are not a sign of the cancer or of its behavior. The symptoms that would matter, new persistent bone pain, especially in the back or hips, or new inability to pass urine, belong to a different stage and are not part of a low-risk surveillance story. Feeling well is your baseline, and the job of the whole surveillance schedule is to keep it that way while the watching does the work.